First-of-its-kind approach nanomedicine design effectively targets cancer with decreased toxicity

Jul 10, 2012

Researchers at Brigham and Women's Hospital (BWH) are the first to report a new approach that integrates rational drug design with supramolecular nanochemistry in cancer treatment.

Supramolecular chemistry is the development of complex chemical systems using molecular building blocks. The researchers utilized such methods to create nanoparticles that significantly enhanced antitumor activity with decreased toxicity in breast and models.

"This work is effectively moving beyond using nanotechnology as drug 'delivery' vehicles to reengineering drugs themselves so that they become nanomedicines." said Shiladitya Sengupta, PhD, MSc, BWH associate , and senior study author.

The study is published in this week's issue of the (PNAS).

The researchers used cisplatin—a drug of choice for first and second line chemotherapy—as a template.

They designed a cisplatin nanoparticle that incorporated various components, namely a unique platinum (II) tethered to a cholesterol backbone, that helped foster an environment that facilitated efficient nanoparticle assembly.

The researchers found that the innovative nanoparticles they developed were more effective compared to carboplatin or cisplatin in vitro, and remained active in -resistant conditions.

"In the last 30 years, there have only been three platins that have been approved for use in almost all cancers," said Sengupta. "A fourth platin that homes preferentially to the tumor, is more potent, but is safer to use at the same time can have major impact on chemotherapy."

Given that platinum-based chemotherapies serve as the frontline therapy for many cancers, the researchers are optimistic that the increased efficacy and toxicity profile demonstrated by their design may lead to the next generation platinum-based agents in the fight against cancer.

Explore further: Nano-scale gold particles are good candidates for drug delivery

Related Stories

Super-sizing a cancer drug minimizes side effects

Jul 28, 2010

One of the first chemotherapy drugs given to patients diagnosed with cancer — especially lung, ovarian or breast cancer — is cisplatin, a platinum-containing compound that gums up tumor cells’ DNA. Cisplatin ...

Using nanotechnology to improve a cancer treatment

Jun 28, 2010

(PhysOrg.com) -- Harvard and Brigham and Women’s Hospital researchers have devised a method that may allow clinicians to use higher doses of a powerful chemotherapy drug that has been limited because it is toxic not only ...

Gold used as safe driver of cancer drug

Mar 21, 2012

(PhysOrg.com) -- Gold nanoparticles can be used as delivery vehicles for platinum anticancer drugs, improving targeting and uptake into cells, according to research published in this month's edition of the ...

Gold Nanoparticles Delivery Platinum Warheads to Tumors

Oct 29, 2009

(PhysOrg.com) -- Cisplatin is one of the most powerful and effective drugs for treating a wide variety of cancers, but serious side effects ultimately limit the drug's use and effectiveness. Now, however, researchers have ...

A more direct delivery of cancer drugs to tumors

Apr 21, 2009

(PhysOrg.com) -- An interdisciplinary team of researchers at Brigham and Women’s Hospital (BWH) and the Harvard-MIT Division of Health Sciences and Technology (HST) has demonstrated a better way to deliver ...

Recommended for you

A crystal wedding in the nanocosmos

Jul 23, 2014

Researchers at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), the Vienna University of Technology and the Maria Curie-Skłodowska University Lublin have succeeded in embedding nearly perfect semiconductor ...

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

wealthychef
not rated yet Jul 10, 2012
Cool. Now if we can speed up the glacial rate of drug and therapy approvals, by focusing on methods of verifying efficacy and safety quickly and accurately, then we have a huge win. Because right now, the rate of innovation in medicine is completely roadblocked by the necessity of going through the lengthy process of clinical trials.
Birger
5 / 5 (1) Jul 10, 2012
I understand the need for long clinical trials, but could not there be an "express lane" for such anti-cancer medicines for those patients who are only expected to live a year or less? If those patients sign a waiver, it should solve the legal problems for the hospitals.